Acorda Therapeutics Stock News

Coronavirus (Covid-19) Vaccine Latest Update: From Oxford University's coronavirus vaccine trial on rhesus macaque monkeys showing promise to a vaccine made with proteins from tobacco leaves ready for

Longevity is potentially a trillion-dollar industry - until it isn't, because we can't keep the vulnerable safe from the latest pandemic. The Woohoo Flu has us distracted from the longevity thesis for

The word's No. 2 cigarette company claims it has developed an experimental vaccine for the novel coronavirus that has shown promise in laboratory testing and is now ready to be experimented on humans

The market barometers slipped further in mid-morning trade, extending yesterday's steep losses. At 11:25 IST, the barometer index, the S&P BSE Sensex, was down 303.02 points or 0.97% at 30,819.87. The

Unichem Lab stock had hit a 52-week high of Rs 200.60 on the BSE on May 24, 2019, while its 52-week low was Rs 75.10, hit on March 23 this year.

Unichem Laboratories surged 7.89% to Rs 137.50 after the company received the establishment inspection report (EIR) from the USFDA for its facility at Roha, Maharashtra.

All that happened in the markets today

Brokerage firm Prabhudas Lilladher has upgraded Lupin's stock to 'Buy' from earlier 'Reduce' with target price of Rs 978

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data an

André Gagnon, a spokesman for Health Canada, said the department has been looking at the Canadian supply chain to identify areas where supply may be vulnerable, and addressing any weaknesses before s

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod

S&P; Dow Jones Indices will make the following changes to the S&P; 500, S&P; 100, S&P; MidCap 400, and S&P; SmallCap 600 effective prior to the opening on Tuesday, May 12:

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandem